Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Orthocell Ltd ( (AU:OCC) ) just unveiled an announcement.
Orthocell Ltd has announced the use of its nerve repair device, Remplir, in nerve-sparing robotic-assisted radical prostatectomies (RARP) in Australia, aiming to reduce post-surgical complications such as erectile dysfunction and urinary incontinence. This development represents a significant opportunity for Orthocell to expand Remplir’s market presence, as the product is being adopted by urologists to protect and restore nerve function during prostate cancer surgeries, potentially increasing its global total addressable market.
The most recent analyst rating on (AU:OCC) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Ltd is a regenerative medicine company based in Perth, Australia, specializing in innovative nerve repair solutions. Their flagship product, Remplir, is a nerve wrap used in peripheral nerve repair procedures, and the company is focused on expanding its applications across various surgical specialties, including orthopaedics, plastic and reconstructive surgery, and urology.
Average Trading Volume: 583,666
Technical Sentiment Signal: Buy
Current Market Cap: A$275.9M
See more data about OCC stock on TipRanks’ Stock Analysis page.